Clinical Trials Browser

INDUSTRY × Has results × Axitinib × Clear all

Carcinoma, Renal Cell

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms

Carcinoma, Renal Cell

Carcinoma, Renal Cell

Solid Tumors

Carcinoma, Renal Cell

Carcinoma, Renal Cell

Carcinoma, Lymphoma, Mantle-Cell

Kidney Neoplasms

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

Carcinoma, Renal Cell

Carcinoma, Neoplasms

Kidney Neoplasms

Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms

Carcinoma, Renal Cell

Carcinoma, Renal Cell

Carcinoma, Hepatocellular, Liver Diseases, Neoplasms

Carcinoma, Renal Cell

Carcinoma, Renal Cell

Pancreatic Neoplasms

Kidney Neoplasms

Carcinoma, Hepatocellular

Carcinoma, Renal Cell

Carcinoma, Renal Cell, Kidney Neoplasms

Carcinoma, Non-Small-Cell Lung

Colorectal Neoplasms

Stomach Neoplasms

Carcinoma, Thyroid Neoplasms

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung

Colorectal Neoplasms

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Carcinoma, Renal Cell, Kidney Neoplasms

Carcinoma, Pancreatic Ductal

Breast Neoplasms

Thyroid Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Melanoma, Skin Neoplasms

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Carcinoma, Renal Cell

Advanced Solid Tumors

Clinical Trials

KEYNOTE-426

Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)

JAVELIN Renal 101

J-DART2

To Examine the Effects of Axitinib Dose Reduction and Interruption for Adverse Event Management Among Patients Receiving Axitinib in for the Treatment of Advanced Renal Cell Carcinoma

Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials

A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma

Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma

STAR-TOR

Treatment Patterns With Targeted Therapies In Mrcc In Sweden - A Retrospective Analysis Of Data From National Registries

A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)

Current Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART)

Study of Patients With Metastatic and/or Advanced Renal Cell Carcinoma, Treated With Sunitinib/Axitinib.

Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer

JAVELIN Renal 100

A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer

Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma

A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors

A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100)

ATLAS

Study Of AG-013736 (Axitinib) As Second-Line Treatment In Patients With Metastatic Renal Cell Cancer (mRCC)

AG-013736 In Combination With Gemcitabine Versus Gemcitabine Alone For Patients With Metastatic Pancreatic Cancer

Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer

Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma

PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma

Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer

Evaluation Of The Efficacy Of The Combination Of Axitinib With Pemetrexed And Cisplatin In The Treatment Of Non-Squamous Non-Small Cell Lung Cancer

Study With AG-013736 Combined With Chemotherapy And Bevacizumab In Patients With Metastatic Colorectal Cancer

Study Of Axitinib In Combination With Cisplatin And Capecitabine In Patients With Advanced Gastric Cancer

Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer

A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.

A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen

Trial Of AG-013736, Cisplatin, And Gemcitabine For Patients With Squamous Non-Small Cell Lung Cancer

Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer

Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.

AG-013736 In Combination With Docetaxel Versus Docetaxel Alone For Patients With Metastatic Breast Cancer

Study of the Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer

Anti-angiogenesis Agent AG-013736 in Patients With Advanced Non-Small Cell Lung Cancer

Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic Melanoma

AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS)

Study Of AG-013736 (Axitinib) In Patients With Advanced Solid Tumors

A Study In Patients With Advanced Solid Tumor

Retrospective Observational Study To Update 5-Year Survival Of Subjects Who Participated In Axitinib Trial A4061012

Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor

First In Human, Phase 1 Study of AG013736 In Patients With Solid Tumors